Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Effects of ceruletide on perioral movements and the dopamine receptor-adenylate cyclase system in rats chronically treated with fluphenazine


The effects of repeated administration of ceruletide (100 µg/kg/perday, IP for 3 days) on perioral movements and the striatal dopamine receptor adenylate cyclase system were examined in rats chronically treated with fluphenazine enanthate (FPZ) (25 mg/kg IM every 3 weeks for 30 weeks) and sesame oil-treated (control) rats. After the tenth injection of fluphenazine, the rats started to display five types of perioral movements (teeth chattering, chewing, tongue protrusion, mouth opening and perioral tremors). Moreover, increases in SCH23390 binding and spiperone binding to striatal membranes were found in the FPZ-treated rats. Furthermore, dopamine receptor-coupled adenylate cyclase activity was potentiated in striatal membranes. High amplitude EMG discharges (8–10 Hz), recorded from the masseter in the FPZ-treated rats occurred concurrently with perioral tremors. Repeated ceruletide (CLT) injections abolished perioral movements, and reversed both the elevated SCH23390 binding and the dopamine stimulated adenylate cyclase (AC) activity to the control level. The effect of CLT on perioral movements, D1 receptors and dopamine-stimulated AC activity continued for 6 days after the final CLT injection. These finding suggest that systemically administered CLT affects the D1 receptor adenylate cyclase system and that an increase of the D1 receptor mechanism may play an important role in the pathogenesis of tardive dyskinesia.

This is a preview of subscription content, log in to check access.


  1. Billard W, Ruperto V, Grosby G, Lorlo LC, Barnett A (1984) Characterization of the binding of3H-SCH23390, a selective D-1 receptor antagonist ligand, in rat striatum. Life Sci 35:1885–1893

  2. Clow A, Jenner P, Marsden CD (1979) Changes in dopamine-mediated behavior during one year's neuroleptic administration. Eur J Pharmacol 57:365–375

  3. Clow A, Theodorou A, Jenner P, Marsden CD (1980) Cerevral dopamine function in rats following withdrawal from one year of continuous neuroleptic administration. Eur J Pharmacol 63:145–157

  4. Collins P, Broekkamp CLE, Jenner P, Marsden CD (1991) Drugs acting at D-1 and D-2 dopamine receptors induce identical purposeless chewing in rats which can be differentiated by cholinergic manipulation. Psychopharmacology 103:503–512

  5. Collins P, Broekkamp CLE, Jenner P, Marsden CD (1993a) Electromyographical differentiation of the components of perioral movements induced by SKF38393 and physostigmine in the rat. Psychopharmacology 112:428–436

  6. Collins P, Broekkamp CLE, Jenner P, Marsden CD (1993b) Effect of chronic trifluoperazine administration and subsequent withdrawal on the production and persistence of perioral behaviours in two rat strains. Psychopharmacology 112:437–444

  7. Cooper DMF, Beir-Laning CM, Halford MK, Ahlijanian MK, Zahniser NR (1986) Dopamine, acting through D2 receptors, inhibits rat striatal adenylate cyclase by a GTP-dependent process. Mol Pharmacol 29:113–119

  8. Cote TE, Frey EA, Sekura RD (1984) Altered activity of the inhibitory guanyl nucleotide-binding component (Ni) induced by pertussis toxin. Uncoupling of Ni from receptor with continued couling of Ni to the catalytics unit. J Biol Chem 259:8693–8698

  9. Crawlely JN, Hays SE, Paul SM (1981) Vagotomy abolishes the inhibitory effects of cholecystotinin on rat exploratory behaviors. Eur J Pharmacol 73:379–380

  10. Creese I, Scheneilder R, Snyder SH (1977)3H-spiperoperidol labels dopamine receptors in pituitary and brain. Eur J Pharmacol 46:377–381

  11. Creese I, Sibley DR, Hamblin MW, Left SE (1983) The classification of dopamine receptors: relationship to radiology and binding. Annu Rev Neurosci 6:43–71

  12. Ellision G, See R, Levin E, Kinney J (1987) Tremorous mouth movements in rats administered chronic neuroleptics. Psychopharmacology 92:122–126

  13. Emson PC, Lee CM, Rehfeld JF (1980) Cholecystokokinin octapeptide: vesicular localization and calcium dependent release from rat brain in vitro. Life Sci 26:2157–2164

  14. Fuxe K, Andersson K, Locataelli V, Agnati LF, Hökfelt T, Skirboll L, Mutt V (1980) Cholecystokinin peptides produce marked reduction of dopamine turnover in discrete areas in the rat brain following intrventricular injection. Eur J Pharmacol 67:329–331

  15. Gerlach J, Casey DE (1988) Tardive dyskinesia (review article). Acta Psychiatr Scand 77:369–378

  16. Hashimoto T, Yanagisaw N (1990) Acute reduction and long-term improvement of chorea with ceruletide (cholecystokinin analogue). J Neurol Sci 100:178–185

  17. Hatta Y, Hatta S, Satio T (1993) Effect of ceruletide on the dopamine receptor-adenylate cysclasse system in streatum and frontal cortex of rats chronically treated with haloperidol. Psychopharmacology 110:383–389

  18. Hess EJ, Battaglia G, Norman AB, Iorio L, Creese I (1986) Guanine nucleotide regulation of agonist interaction at [3H]SCH23390-labeled D1 dopamine receptors in rat striatum. Eur J Pharmacol 12:31–38

  19. Hökfelt T, Johannsson O, Ljungdarl, Lundberg JM, Schultzberg M (1980a) Peptidergic neurons. Nature 284:515–521

  20. Hökfelt T, Skirbaoll L, Rehfeld JF, Goldstein M, Markey K, Dann O (1980b) A subpopulation of mesencephalic dopamine neurons projecting to limbic areas contains a cholecystokininlike peptide: evidence from immunohistochemistry combined with retrograde tracing. Neuroscience 5:2093–2124

  21. Iversen SD, Howells RB, Huges RP (1980) Behavioral consenquences of long-term treatment with neuroleptic drugs. Adv Biochem Psychopharmacol 24:305–313

  22. Johnsson P, Levin E, Gunne L, Ellison G (1987) Opposite effects of a D1 and a D2 agonist on oral movements in rats. Eur J Pharamacol 134:L83–88

  23. Jurna I, Zetler G (1981) Antinociceptide effect of centrally administered caerulein and cholecystokinmin octapeptide (CCK-8). Eur J Pharamacol 73:323–331

  24. Kaneda H, Shirakawa O, Dale J, Goodman L, Bachus SE, Tamminga CA (1992) Co-administration of progabide inhibits haloperidol-induced oral dysknesias. Eur J Pharmacol 212:43–49

  25. Kebabian JW, Calne DB (1979) Multiple receptors for dopamine. Nature 277:93–96

  26. Kojima T, Yamauchi T, Miyasaka M, Koshino Y, Nakane Y, Takahashi R, Shimazono Y, Yagi G (1992) Treatment of tardive dyskinesia with ceruletide: a double-blind, placebo-controlled study. Psychiatry Res 43:129–136

  27. Kovac GL, Szabo G, Penke B, Telegdy G (1981) Effects of cholecystokinin octapeptide on striatal dopamine metabolism and on apomorphine-induced stereotyped cage-climbing in mice. Eur J Pharmacol 69:313–319

  28. Lal S, Nair NPV, Engenio H, Thavundail J, Linzondo E, Wood PL, Etienne P, Guyada H (1983) Neuroendocrine evaluation of CCK-peptides on dopaminergic function in man. Prog Neuropsychopharmacol Biol Psychiatry 7:537–544

  29. Lane RF, Blaha CD, Philips AG (1986) Cholecystokinin-induced inhibition of dopamiine neurotransmission: comparison with chronic haloperidol treatment. Prog Neuropsychopharmacol Biol Psychiatry 11:291–299

  30. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951) Protien measurementy with the Folin phenol reagent. J Biol Chem 193:265–275

  31. Markstein R, Hökfelt T (1984) Effect of cholecystokinin-octapeptide on dopamine release from slices of cat caudate nucleus. Neuroscience 4:570–575

  32. Matsubara K, Matsushita A (1985a) Possible involvement kof the central nervous system in long-term effect of caerulein on amphetamine-induced hyperactilvity in rats. Jpn J Pharmacol 39:317–321

  33. Matsubara K, Matsushita A (1985b) Analysis of the long-lasting antagonistic effect of caerulein on amphetamine hyperactivity in rats. Jpn J Pharmacol 38:381–390

  34. Matsumoto T, Nakahara T, Uchimura H, Hirano M, Yokoo H, Nakamura K, Oomagari K (1984) Effect of systemically administered caerulein on dopamine metavolism in rat brain. Brain Res 324:195–199

  35. Moroji T, Hagino Y (1986) A behavioral pharmacological study on CCK-8 related peptides in mice. Neuropeptides 8:273–286

  36. Moroji T, Hagino Y (1987) Bilateral subdiapharagmatic vagotomy does not prevent the behavioral effects of systematically administered ceruletide in mice. Neuropeptides 9:217–224

  37. Nishikawa T, Tanka M, Koga I, Uchida Y (1985) Biphasic and long-lasting effect of ceruletide on tardive dyskinesia. Psychopharmacology 86:43–44

  38. Onali P, Olianas MC, Glessa GL (1984) Selective blockade of dopamine D-1 receptors by SCH23390 discloses striatal dopamine D-2 receptors mediating the inhibition of adenylate cysclase in rats. Eur J Pharmacol 99:127–128

  39. Onali P, Olianas MC, Glessa GL (1985) Characterization of dopamine receptors mediating inhibition of adenylate cyclase activity in rat striatum. Mol Pharmacol 28:138–145

  40. Peacock L, Lublin H, Gerlach J (1990) The effects of dopamine D1 and D2 receptor agonists and antagonists in monkeys withdrawn from long-term neuroleptic treatment. Eur J Pharmacol 186:49–59

  41. Rosengarten H, Schweitzer JW, Friedhoff AJ (1983) Induction of oral dyskinesias in naive rats by D1 stimulation. Life Sci 33:2479–2482

  42. Saito T, Lee JM, Tabakoff B (1985) Ethanol's effects on cortical adenylate cyclase activity. J Neurochem 44:1037–1044

  43. Salomon Y, (1979) Adenylate cyclase assay. Adv Cyclic Nucleotide Res 10:35–55

  44. See RE, Ellison G (1990) Intermittent and continuous haloperidol regimens produce different types of oral dyskinesia in rats. Psychopharmacology 100:404–412

  45. Skirboll LR, Grace AA, Hommer DW, Rehfeld J, Goldstein M, Hökfelt T, BAunney Bs (1981) Peptide -monoamine coexistence: studies of the actions of cholecystokinin-like peptide on the electrical activity of midbrain dopamine neurons. Neuroscience 6:2111–2124

  46. Stoessl AJ, Dourish CT, Iversen SD (1989) Chornic neuroleptic-induced mouth movements in the rat: supression by CCK and selective dopamine D1 and D2 receptor antagonists. Psychopharmacology 98:372–379

  47. Stoof JC, Kebabian JW (1981) Oppositing roles for D-1 and D-2 dopamine receptors in efflux of cyclic AMP from rat neostriatum. Nature 294:366–368

  48. Stoof JC, Kebabian JW (1984) Two dopamine receptors: biochemistry, physiology and pharmacology. Life Sci 35:2281–2296

  49. Tanaka H (1990) Absorption, distrubtion and excretion of 883-S (ceruletide diethylamine) in rats. Xenobiot Metabol Dispos 5:331–343

  50. Voight MM, Wang RY (1984) In vivo release of dopamine in the nucleus accumbens of the rat: modulation by cholecystokinin. Brain Res 296:189–193

  51. Waddington JL (1990) Spontaneous orofacial movements induced in rodents by very long-term neuroleptic drug administration: phenominology, pathophysiology and putative relationship to tardive dyskinesia. Psychopharmacology 101:431–447

  52. Waddington JL, Cross AJ, Gamble SJ, Bourne RC (1983) Spontaneous orofacial dyskinesia and dopaminergic function in rats after 6 months of neuroleptide treatment. Science 220:530–532

  53. Willner P (1984) The validity of animal models of depression. Psychopharmacology 83:1–16

  54. Zetler G (1980a) Analgesia and jptosis caused by caerulein and cholecystokinin octapeptide (CCK-8). Neuropharmacology 19:415–422

  55. Zetler G (1980b) Effects of cholecystoknin-like peptides on rearing activity and hexobarbital-induced sleep. Eur J Pharmacol 66:137–139

  56. Zetler G (1980c) Anticonvulsant effects of caerulein and cholecystokinin octapeptide, compared with those of diazepam. Eur J Pharmacol 65:297–300

  57. Zetler G (1981) Central depressant effect of caerulein and cholecystokinin octapeptide (CCK-8) differ from those of diazepam and haloperidol. Neuropharmacology 20:277–283

Download references

Author information

Correspondence to T. Saito.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Ashizawa, T., Saito, T. & Takahata, N. Effects of ceruletide on perioral movements and the dopamine receptor-adenylate cyclase system in rats chronically treated with fluphenazine. Psychopharmacology 125, 185–194 (1996).

Download citation

Key words

  • Ceruletide
  • Tardive dyskinesia
  • Chronic fluphenazine
  • D1 receptor
  • Adenylate cyclase